AP

Alagesan Perumal

Active Director Director DIN 10364076
DIN 10364076 First appointment Oct 2023
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2023
Shareholding value •••• Premium profile

About Alagesan Perumal

Data last updated:

Alagesan Perumal is a Director at Alagubanu Indian Medicines Health Care Private Limited (since 2023). Alagubanu Indian Medicines Health Care Private Limited reported revenue of ₹52,305 (FY 2025).

DIN 10364076
Primary Designation Director
First Appointment 19 Oct 2023
Oldest Company Age 3 yrs
Largest company Alagubanu Indian Medicines Health Care Private Limited · ₹52,305 (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director19 Oct 20232023₹52,305 (FY 2025)Active

Board colleagues of Alagesan Perumal

Directorship timeline

Open interactive timeline →
Alagubanu Indian Medicines Health Care Private Limited
Premium access

Shareholding and investment profile for Alagesan Perumal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Alagesan Perumal

Alagesan Perumal currently holds 1 directorship: Alagubanu Indian Medicines Health Care Private Limited (Director, since 19 Oct 2023, revenue ₹52,305 (FY 2025)).

Alagesan Perumal was first appointed on 19 Oct 2023 as Director at Alagubanu Indian Medicines Health Care Private Limited.

The current boards of Alagesan Perumal's companies include Raju Banupriya (Alagubanu Indian Medicines Health Care Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available